Skip to content

Study · Animal study (in vivo) · rat · 2010

4 results

Chronic hypertension aggravates heat stress-induced brain damage: possible neuroprotection by cerebrolysin.

Muresanu DF, Zimmermann-Meinzingen S, Sharma HS

Acta neurochirurgica. Supplement1 Jan 2010Cited by 12 (Europe PMC)

PMID19812973 (opens in a new tab)DOI10.1007/978-3-211-98811-4_61 (opens in a new tab)PepBankPUB-19812973
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats exposed to heat stress, cerebrolysin pretreatment attenuated BBB dysfunction.

    In plain wordsIn normal rats exposed to heat, cerebrolysin reduced blood-brain barrier dysfunction.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBBB dysfunction in normal rats
    Study

    ratn: not reported in source

    Normotensive rats exposed to heat stress
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mL/kgAs given in this study (rat).

    Source sentences

    Summary
    Pretreatment with cerebrolysin (5 mL/kg, 24 h and 30 min before heat stress) markedly attenuated the BBB dysfunction and brain pathology in normal animals.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats exposed to heat stress, cerebrolysin pretreatment attenuated brain pathology.

    In plain wordsIn normal rats exposed to heat, cerebrolysin reduced brain damage.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBrain pathology in normal rats
    Study

    ratn: not reported in source

    Normotensive rats exposed to heat stress
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mL/kgAs given in this study (rat).

    Source sentences

    Summary
    Pretreatment with cerebrolysin (5 mL/kg, 24 h and 30 min before heat stress) markedly attenuated the BBB dysfunction and brain pathology in normal animals.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In hypertensive rats exposed to heat stress, a high cerebrolysin dose was needed to attenuate BBB dysfunction.

    In plain wordsIn hypertensive rats exposed to heat, a high cerebrolysin dose was needed to reduce blood-brain barrier dysfunction.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBBB dysfunction in hypertensive rats
    Study

    ratn: not reported in source

    Chronic hypertensive rats exposed to whole body hyperthermia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mL/kgAs given in this study (rat).

    Source sentences

    Summary
    However, in hypertensive animals, a high dose of cerebrolysin (10 mL/kg, 24 h and 30 min before heat stress) was needed to attenuate WBH-induced BBB dysfunction and brain pathology.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In hypertensive rats exposed to heat stress, a high cerebrolysin dose was needed to attenuate brain pathology.

    In plain wordsIn hypertensive rats exposed to heat, a high cerebrolysin dose was needed to reduce brain damage.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBrain pathology in hypertensive rats
    Study

    ratn: not reported in source

    Chronic hypertensive rats exposed to whole body hyperthermia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mL/kgAs given in this study (rat).

    Source sentences

    Summary
    However, in hypertensive animals, a high dose of cerebrolysin (10 mL/kg, 24 h and 30 min before heat stress) was needed to attenuate WBH-induced BBB dysfunction and brain pathology.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.